Report contents
At a glance
- Business model: Synopsys sells multi-year, time-based EDA licenses and semiconductor design IP to chip design teams, recognizing revenue ratably over the contract term. EDA is a small slice of a chip program's cost but gates the tape-out, so budgets follow R&D plans rather than quarterly trade-offs. The obstacle is that revenue ultimately tracks design starts and customer R&D budgets.
- Financial quality: Cash conversion has held — FY2025 operating cash flow of $1.52 billion exceeded net income of $1.33 billion, and first-half FY2026 free cash flow of $1.44 billion already tops full FY2025's $1.35 billion. Balance-sheet capacity is thinner: goodwill is $26.85 billion of $46.89 billion in assets, and $2.41 billion of cash sits against long-term debt last disclosed at $14.32 billion.
Business model
Business model: Synopsys sells the tools, not the chips
Synopsys sells software licenses and semiconductor design intellectual property (IP) to the teams that design chips and electronic systems. Its customers are chipmakers, systems and hyperscaler silicon groups, and a widening set of automotive, aerospace, and industrial companies building custom silicon. They pay through multi-year, time-based license and subscription contracts, and in the IP business through license fees plus per-unit royalties. Because most of that revenue is recognized over the contract term rather than at the point of sale, the model throws off deferred revenue and a large remaining performance obligation (RPO — contracted revenue not yet recognized), which is the clearest forward read on the order book.
This is a subscription-style software and IP licensor: mature and highly concentrated at the core, expanding through acquisition at the edges. In its FY2025 Form 10-K (fiscal year ended October 31, 2025), Synopsys reports 191,318,206 shares outstanding as of December 15, 2025 and roughly $59.3 billion of non-affiliate equity value at the end of its second fiscal quarter. Those are cover-page facts, not operating ones.
Who pays: design teams with budgets set before revenue
The direct reason customers pay is tape-out risk. A tape-out is the final handoff of a chip design to manufacturing; an error found afterward means a new mask set and months of lost schedule, so design teams buy tools to catch mistakes earlier. The structural reason the spending is sticky is that EDA (electronic design automation) is a small slice of a chip program's total cost but gates the entire program. Tool budgets are therefore set alongside R&D plans, not traded off against them quarter to quarter, and the purchase decision sits with engineers who will use the tool for years.
The tradeoff: price per seat versus design starts
Synopsys can raise prices because ripping out a design flow mid-project is close to unthinkable — the switching cost is measured in re-verification, not in license fees. The volume side is weaker. Revenue ultimately tracks design starts, which follow customer R&D budgets and the semiconductor cycle, so pricing power and unit demand pull in opposite directions. Multi-year contracts hide the tension: a price increase signed this year shows up gradually, which means reported growth can stay smooth even as the underlying number of new designs falls. That is a real fragility, not a theoretical one, and it is compounded by the geopolitics of who is allowed to design what in China.
A single-minded push on price could also backfire if it pushes cost-sensitive customers toward Cadence, toward internal flows, or toward open-source alternatives at mature nodes — trading future seats for current revenue. The evidence that would settle this: revenue growth holding up while advanced-node design starts soften, or growth carried by pricing with flat seat and customer counts.
What the disclosure here doesn't show — and where the mix is changing
The supplied excerpt is the cover page and table of contents of the FY2025 10-K, so it contains no segment revenue, no geographic split, no customer concentration, and no product mix. That matters more than usual right now. The fiscal 2025 period includes the Ansys acquisition, which management has said closed in July 2025; that combination moves Synopsys beyond core EDA into simulation and multiphysics, which changes who the buyer is inside a customer's engineering organization and how revenue per account is calculated. Nothing in the material provided quantifies that contribution, so any claim about the new mix would be an estimate rather than a reported figure.
Two mechanical points worth keeping straight. Gross margin here means revenue less the cost of delivering licenses and support — mostly personnel, third-party royalties, and amortization — and it is high because shipping an incremental license costs almost nothing; that structure is exactly why incremental revenue drops through quickly, and why a stalled top line hurts. ARPU, or average revenue per user/account, is not a metric Synopsys discloses in the excerpt, so it cannot be tracked from this evidence.
The judgment: this is a high-quality, non-discretionary subscription business with genuine switching costs, now absorbing a large acquisition into its mix. The core question for the next two years is whether the combined portfolio sells more into existing design budgets, or simply adds revenue that carries a lower margin and a slower renewal rhythm.
Financial quality
Financial quality: the cash engine held; the reported returns did not
Synopsys still converts revenue into cash at close to the rate it did before the acquisition that closed in the quarter ended July 31, 2025. Almost everything else changed. Total assets went from $13.1 billion at FY2024 year-end to $48.2 billion; goodwill from $3.4 billion to $26.9 billion; long-term debt from roughly nothing to $14.3 billion (last disclosed separately at FY2025 Q3). Operating income fell to $0.92 billion in FY2025 and $0.20–0.24 billion a quarter in the first half of FY2026, while free cash flow was $1.35 billion in FY2025 and $1.44 billion in the first half of FY2026, against $0.11 billion in the year-earlier half.
| USD bn unless noted | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY26 Q1 (3 mo) | FY26 Q2 (3 mo) | Assessment |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.20 | 4.62 | 5.32 | 6.13 | 7.05 | 2.41 | 2.28 | Strong |
| Gross margin % | 78.7 | 80.5 | 76.9 | 79.7 | 77.0 | 73.4 | 72.4 | Adequate |
| Operating income | 0.73 | 1.15 | 1.27 | 1.36 | 0.92 | 0.20 | 0.24 | Weak |
| Net income | 0.76 | 0.98 | 1.23 | 2.26 | 1.33 | 0.07 | 0.02 | Weak |
| Net margin % | 18.0 | 21.3 | 23.1 | 36.9 | 18.9 | 2.9 | 0.9 | Weak |
| ROE % | 14.8 | 18.2 | 21.1 | 29.9 | 4.7† | n.a. | n.a. | Very weak now |
| Liabilities/assets % | 39.5 | 41.0 | 40.2 | 31.0 | 41.3 | 35.3 | 35.0 | Adequate |
| Current ratio | 1.16 | 1.09 | 1.15 | 2.44 | Not disclosed | Not disclosed | Not disclosed | Thin coverage |
| Asset turnover | 0.50 | 0.51 | 0.54 | 0.52 | 0.15† | n.a. | n.a. | Weak, deal-driven |
| Operating cash flow | 1.49 | 1.74 | 1.70 | 1.41 | 1.52 | 0.86 | 0.67 | Strong |
| Free cash flow | 1.40 | 1.60 | 1.51 | 1.28 | 1.35 | 0.82 | 0.62 | Strong |
| Operating cash flow / net income | 1.96 | 1.78 | 1.38 | 0.62 | 1.14 | n.m. | n.m. | Mixed |
| Long-term debt | 0.0 | 0.02 | 0.02 | 0.02 | 14.3‡ | Not disclosed | Not disclosed | Adequate but new |
| Goodwill / total assets % | 40.9 | 40.8 | 32.4 | 26.4 | 55.8 | 56.9 | 57.3 | Weak |
†FY2025 ratios use year-end balances; the mid-year acquisition makes any average unrepresentative. ‡Last disclosed at FY2025 Q3. n.m. = not meaningful on a single quarter.
| USD bn unless noted | FY25 Q1 | FY25 Q2 | FY25 Q3 | FY25 Q4 | FY26 Q1 | FY26 Q2 | Assessment | Trend |
|---|---|---|---|---|---|---|---|
| Revenue | 1.46 | 1.60 | 1.74 | 2.25 | 2.41 | 2.28 | Deal-boosted, flat sequentially |
| Gross margin % | 81.5 | 80.6 | 78.1 | 71.1 | 73.4 | 72.4 | 9 pts below FY25 Q1 |
| Operating income | 0.25 | 0.38 | 0.16 | 0.12 | 0.20 | 0.24 | Weak but stabilizing |
| Net income | 0.30 | 0.35 | 0.24 | 0.45 | 0.07 | 0.02 | Collapsing |
| Total assets | 13.04 | 23.76 | 48.23 | 48.22 | 47.24 | 46.89 | Step change, then flat |
| Total liabilities | 3.74 | 13.84 | 20.62 | 19.90 | 16.69 | 16.41 | Deleveraging slowly |
| Fixed assets (net PP&E) | Not disclosed | Not disclosed | Not disclosed | Not disclosed | Not disclosed | Not disclosed | — |
| Operating cash flow | (0.07) | 0.28 | 0.67 | 0.64 | 0.86 | 0.67 | Steady, seasonal Q1 dip |
| Free cash flow | (0.11) | 0.22 | 0.63 | 0.60 | 0.82 | 0.62 | Steady |
| Cash | 3.65 | 14.12 | 2.53 | 2.89 | 2.13 | 2.41 | Deal funding consumed |
| Goodwill | 3.43 | 3.46 | 26.95 | 26.90 | 26.88 | 26.85 | Flat since closing |
| Interest expense | 0.01 | 0.09 | 0.15 | 0.20 | 0.16 | 0.13 | New, material |
The profit line broke; the cash line did not
Gross margin slipped from 81.5% in FY2025 Q1 to 72.4% in FY2026 Q2, more than 3 percentage points below the prior-year level, and the supplied data don't separate pricing, IP mix, and purchase-accounting amortization. The bigger break is further down: the gap between gross profit and operating income widened to $4.5 billion in FY2025 from $3.5 billion in FY2024, and operating margin is now near 9%. The statements don't split that cost between amortization of acquired intangibles and stock-based compensation. That split matters more than any other missing number, because management's Investor Day in September 2026 targets a ~50% non-GAAP operating margin by FY2030. A gap that wide is only defensible if most of it is amortization that fades.
Cash keeps coming. Operating cash flow was $1.4–1.7 billion every year from FY2021 through FY2025, and cash conversion ran above 1.0 in FY2025 and the first half of FY2026 even as GAAP profit collapsed — the signature of non-cash charges. The genuinely weak conversion year was FY2024 (operating cash flow/net income 0.62), and in that year net income of $2.26 billion exceeded operating income of $1.36 billion by about $0.9 billion, meaning a sizeable non-operating gain sat under a 29.9% ROE. The supplied statements don't identify it. Treat the FY2024 return figure and the FY2025–FY2026 collapse as two different distortions, not a trend.
Debt service is affordable; the buyback competes with it
Interest expense runs $0.13–0.16 billion a quarter. GAAP operating income barely covers that in some quarters; EBITDA of $0.49–0.61 billion covers it roughly three to five times. Cash of $2.41 billion is about 17% of the debt, so repayment depends on continuing operating cash flow of roughly $0.7–0.9 billion a quarter — comfortable today, thinner in a soft year. The company said in September 2026 that it intends to repurchase roughly $1 billion of stock while returning up to half of free cash flow, and FY2026 Q1 showed a $1.58 billion financing outflow. Repaying debt and buying shares draw on the same account.
Goodwill is now the returns denominator
Goodwill is 57% of assets and nearly all of the $30.5 billion of equity; tangible book value is a small fraction of that. Asset turnover fell from 0.52 to roughly 0.2 annualized. That is a deal artifact rather than proof the EDA and IP businesses earn worse returns on the assets they actually use — but it does mean FY2027 guidance of about 15% growth to $11.15 billion has to arrive for the $26.9 billion to justify what was paid. Impairment testing rests on those same projections.
Working capital has gone dark
Receivables and inventory stop appearing in the supplied balance sheet after FY2025 Q3, when receivables of $1.39 billion covered roughly 73 days of that quarter's revenue against about 53 days in FY2024 — the direction you would expect as milestone-billed IP grows, but worth checking in the filings. FY2025 Q1's negative operating cash flow shows the seasonality that makes any single quarter a poor guide. Two disclosures would change my read: the GAAP-to-non-GAAP reconciliation split between intangible amortization and stock compensation, and the debt maturity schedule behind the buyback plan.
Questions worth following
- Can Synopsys lift GAAP operating margin back toward 20% as acquisition charges roll off?
GAAP operating margin fell to about 9% in the first half of FY2026 while free cash flow stayed near $1.4 billion a year. The gap is either non-cash acquisition amortization that fades, or recurring costs that do not. Which one it is decides whether reported earnings ever resemble the cash the business produces.
- Will Synopsys reduce its acquisition debt faster than it repurchases stock?
The acquisition added roughly $14 billion of debt and about $0.5 billion of annual interest against quarterly operating income of $0.15–0.24 billion. Whether cash goes to repayment or to buybacks decides how much refinancing and covenant risk Synopsys carries if demand slows.
- Can Synopsys convert design-win momentum into collected cash rather than receivables?
Receivables turnover weakened in the July 2025 quarter as IP work grew, and milestone billing can push collection behind revenue recognition. If that continues, growth gets financed by the balance sheet rather than by customers, which lowers the quality of the revenue Synopsys is adding.
Generated by DeepVal AI. Data and models may contain errors or be outdated. For research only; not personalized investment advice.
Continue reading the full report
- Key risksWhat could break the investment case
- Valuation and margin of safetyWhat the current price assumes, and how much room for error it leaves
- SummaryOur overall judgement and what to watch next
Free to sign up · 20 research points · unlocking this report uses 10
20 points cover 2 full reports. No card needed.
Research reflects its generation date. Preview the first two modules.
More on Synopsys Inc
Synopsys Inc
Business, moat and key questions
Open company page